ENV-294 for Moderate-to-Severe Asthma
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
Recruiting
Phase 2
Interventional Study
Asthma
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- Enveda Therapeutics · Industry
Who this trial is looking for
This trial is looking for adults with moderate to severe asthma. Participants will take either the study drug ENV-294 or a placebo once a day for 12 weeks while continuing their asthma treatments.
Are You a Good Fit for This Trial?
You may be able to join if
- I can read and sign an informed consent form.
- I am between 18 and 75 years old.
- I have had moderate to severe asthma for at least 12 months.
- I have been on inhaled corticosteroids and a long-acting beta₂-agonist for at least 2 months.
- My lung function is between 50% and 80% of normal.
- I have had at least one asthma exacerbation in the past year.
You may not be able to join if
- I have had a moderate or severe asthma exacerbation in the last 4 weeks.
- I have a history of life-threatening asthma.
- I have other significant lung diseases.
- I have had bronchial thermoplasty in the last 2 years.
- I currently have uncontrolled other illnesses.
- I have used biologic therapies for asthma in the last 6 months.
- I smoke or have a significant smoking history.
- I have uncontrolled high blood pressure.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA).
Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of u…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Able to read, understand, and sign an informed consent form before any study procedures
* Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months
* Receiving stable treatment with an inhaled corticosteroid (ICS) …
Contacts